BioXcel Therapeutics

BioXcel presented data from the phase‑3 SERENITY At‑Home study showing that BXCL501 (sublingual dexmedetomidine) reduced agitation in bipolar disorder and schizophrenia versus placebo across all severity levels, with the strongest effect in severe episodes. The benefit was maintained with repeated self‑administrations over the 12‑week study. The FDA set November 14, 2026 as the target date for a decision on the sNDA for IGALMI for at‑home use. The stock recently rose, and the company has a weak financial assessment with a market capitalization of USD 40.45 million, according to InvestingPro. » Plus sur de.investing.com

BioXcel Therapeutics issued, as part of the ninth amendment to its loan agreement, warrants to acquire up to 1,353,729 common shares at an exercise price of $0.01 with a seven‑year term. The issuance occurred at a stock price of $1.15 (market capitalization about $31.4 million) and was covered by a registration rights agreement; the securities were issued pursuant to Section 4(a)(2) and declared to be held as investment. Additionally, the company reported the first patient dosed in a Department of Defense‑funded phase 2a study for BXCL501 and the FDA’s acceptance of an sNDA for IGALMI with a target decision date of November 14, 2026; H.C. Wainwright reaffirmed a buy recommendation with an adjusted price target of $5.00. » Plus sur de.investing.com

BioXcel Therapeutics completed a registered direct placement, raising roughly $8.0 million in gross proceeds from the sale of 4,500,785 common shares including warrants at a combined price of $1.739 per share. The issued warrants are exercisable immediately, entitle the holder to purchase an additional 4,500,785 shares at $1.614 per share, and expire in five years. Existing investor warrants for 1,385,083 shares were reduced to an exercise price of $1.614 and extended to five years; Rodman & Renshaw served as exclusive placement agent. BioXcel uses artificial intelligence to develop neuroscience drugs and, according to InvestingPro, does not expect to be profitable this year. » Plus sur de.investing.com